FDA Approves Inavolisib Combo in PIK3CA+ Advanced Breast Cancer
Data from the INAVO120 trial support the approval of the inavolisib combination for those with PIK3CA-mutant breast cancer.
Forming Connections and Making a Difference in the Brain Cancer Field
The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.
Durvalumab Shows Manageable Safety Profile in LS-SCLC
Results showed of the phase 3 ADRIATIC study found that treatment with durvalumab elicited similar radiation pneumonitis incidences vs placebo for LS-SCLC.
Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Gene Expression Test May Predict Added Atezolizumab Benefit in TNBC
Phase 2 data indicate that the use of DetermaIO was predictive of a pathologic complete response with the addition of immunotherapy to chemotherapy in TNBC.
Post-Transplant Daratumumab Combo Increases MRD Negativity in NDMM
Data support the addition of daratumumab to standard lenalidomide maintenance in patients with newly diagnosed multiple myeloma following transplant.
